This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CTI Reports Final Results From Cooperative Group And NCI-Sponsored Trial Of Brostallicin In Patients With Metastatic Triple-Negative Breast Cancer

References

  1. American Cancer Society. Available at http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-breast-cancer-types   Accessed May 2013. 
  2. Chacon, Renaldo;Constanzo Maria. "Triple-negative breast cancer." Breast Cancer Research. 12(suppl 2):S3 (2010). Available at http://breast-cancer-research.com/content/12/S2/S3. Accessed May 2013.
  3. Living Beyond Breast Cancer: Guide to Understanding Triple-Negative Breast Cancer 2nd Edition 2012. Available at http://www.lbbc.org/Understanding-Breast-Cancer/Guides-to-Understanding-Breast-Cancer/Guide-to-Understanding-Triple-Negative-Breast-Cancer. Accessed May 2013.

CTI Media and Investor Contacts:

Monique Greer+1 206.272.4343 mgreer@ctiseattle.com

Ed Bell+1 206.282.7100 invest@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch

Laura VillaElena Bellacicca

E: CTI_EUInvestors@CTI-Lifesciences.comT: +39 02 89659700F: +39 02 89659719 http://www.celltherapeutics.com/italiano

SOURCE Cell Therapeutics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs